Insulin resistance and decreased spexin in Indian Patients with Type 2 Diabetes Mellitus.

Autor:	Tejaswi G; Department of Biochemistry, Sri Devaraj Urs Academy of Higher Education & Research, Kolar, Karnataka, India., Dayanand CD; Department of Biochemistry, Sri Devaraj Urs Academy of Higher Education & Research, Kolar, Karnataka, India., Prabhakar K; Department of General Medicine, Sri Devaraj Urs Academy of Higher Education & Research, Kolar, Karnataka, India.
Jazyk:	angličtina
Zdroj:	Bioinformation [Bioinformation] 2021 Sep 30; Vol. 17 (9), pp. 790-797. Date of Electronic Publication: 2021 Sep 30 (Print Publication: 2021).
DOI:	10.6026/97320630017790
Abstrakt:	Spexin is novel biomarker, which plays a potential role in glucose and lipid metabolisms. However, there was paucity of serum spexin levels in obesity and diabetes mellitus subjects. Hence the current study was aimed to find the relationship between the serum spexin levels in type 2 Diabetes mellitus (type 2 DM) with extrapolation of cardiovascular disease (CVD) risk. A cross-sectional study included 330 participants, subdivided as control (n=110), type 2 DM (n=110) and type 2 DM with CVD groups (n=110). HbA1c, insulin, lipid profile, spexin & leptin including blood pressure and body mass index were analyzed from all the participants. The serum spexin levels (ng/ml) were significantly decreased in type 2 DM (mean ± sd: 0.65 ± 0.03) and type 2 DM with CVD (0.48 ± 0.02) groups compared to the control (0.79 ± 0.03) group (p<0.001). The decreased spexin levels were observed in type 2 DM, and further more decreased in type 2 DM with CVD patients compared to controls indicating that spexin levels could be served as an early prediction of obesity-induced T2DM with CVD risk. Competing Interests: Authors declares that there is no conflict of interest (© 2021 Biomedical Informatics.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu